Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity

Marion Escudier (1, 2) , Jennifer Cautela (2, 1) , Nausicaa Malissen (3) , Yann Ancedy (4, 5, 6) , Morgane Orabona (2, 1) , Johan Pinto (2, 1) , Sandrine Monestier (7, 1) , Jean-Jacques Grob (8) , Ugo Scemama (2, 1) , Alexis Jacquier (9) , Nathalie Lalevee (10) , Jeremie Barraud (2, 1) , Michael Peyrol (2, 1) , Marc Laine (2, 1) , Laurent Bonello (11, 12) , Franck Paganelli (12, 11) , Ariel Cohen (6, 4) , Fabrice Barlesi (2) , Stephane Ederhy (6) , Franck Thuny (2, 1)

1 AMU - Aix Marseille Université
2 Hôpital Nord [CHU - APHM]
3 Département de dermatologie [CHU de Montpellier]
4 Thrombose, atherothrombose et pharmacologie appliquée
5 CHU Tenon [AP-HP]
6 CHU Saint-Antoine [AP-HP]
7 TIMONE - Hôpital de la Timone [CHU - APHM]
8 Département de dermatologie, CHU Marseille
9 CRMBM - Centre de résonance magnétique biologique et médicale
10 TAGC - Technologies avancées pour le génôme et la clinique
11 Physiopathologie de l'Endothelium
12 VRCM - Vascular research center of Marseille

Immune checkpoint inhibitors (ICIs) represent a major advance in the treatment of cancer. Although clinical trials reported a low incidence of immune-related cardiovascular adverse events, the number of published life-threatening cases of cardiotoxicity is increasing. In this descriptive observational analysis, we aimed to describe the clinical manifestations, management, and outcomes of patients who developed ICI-related cardiotoxicity.

Domaines: Pharmacologie; Cancer; Cardiologie et système cardiovasculaire

Marion Escudier, Jennifer Cautela, Nausicaa Malissen, Yann Ancedy, Morgane Orabona, et al.. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation, 2017, 136 (21), pp.2085-2087. ⟨10.1161/CIRCULATIONAHA.117.030571⟩. ⟨hal-01729764⟩